Garrison L, Midthun K, Clayman B, Smith G, Viscidi R; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 543 (abstract no. M.C.P.12).

Johns Hopkins University, Baltimore, Maryland USA

OBJECTIVE: To characterize the kinetics, magnitude and duration of serum antibody responses of healthy adults participating in a multicentered phase 1 safety and immunogenicity trial of baculovirus expressed gp160 (rgp160) of HIV-1 (VaxSyn HIV-1 MicroGeneSys, Inc.) METHODS: 33 HIV seronegative volunteers were vaccinated at 0, 1 and 6 months with 40 or 80 ug rgp160 (N=24) or a control preparation (N=9). Coded blood specimens obtained from volunteers before and at 0.5, 1, 1.5, 2, 4, 6, 6.5, 7 and 9 months after vaccination were tested for IgG antibody responses by Biotech/Dupont Western blot (WB), Abbott HIV EIA, and noncompetitive solid phase enzyme immunoassay (EIA) using rgp160 as antigen. The specificity of rgp160 EIA was confirmed by a blocking assay. RESULTS: The rgp160 EIA was the most sensitive assay for detecting serum antibody responses in rgp160 vaccinees. Of 23 vaccinees with antibody responses by any assay, 96% were detected by rgp160 EIA, 91% by WB, and 39% by Abbott HIV EIA. The agreement between the rgp160 EIA and WB results was 91% compared to 58% for the rgp160 EIA and Abbott HIV EIA. The specificity of the tests was 100% each for the rgp 160 EIA and WB and 90% for Abbott HIV EIA. The kinetics and magnitude of antibody responses in sera of vaccinees were characterized by the rgp160 EIA. Of the 22 vaccinees detected by rgp160 EIA, 17% had a significant rise in antibody titer after the first, 73% after the second, and 100% after the third vaccination. After the second and third vaccinations, the level of antibody increased 3.6-fold and 6.3-fold above the prevaccination level. By 9 months after the initial vaccination (3 months after the third dose), the level of antibody had declined but remained elevated above prevaccination levels. CONCLUSIONS: The rgp160 EIA was more sensitive than the WB or Abbott HIV EIA, and detected serum IgG antibody responses to rgp160 in 22 of 24 vaccinees. This EIA made it possible to quantitate the magnitude of anamnestic responses to the second and third doses of vaccine and to determine the duration of responses over the 9-month period after vaccination.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Animals
• Antibody Formation
• Blotting, Western
• Equine Infectious Anemia
• Gene Products, env
• HIV Infections
• HIV Seropositivity
• HIV-1
• Immunoenzyme Techniques
• Kinetics
• Protein Precursors
• Vaccination
• VaxSyn HIV-1 (gp160) vaccine
• immunology

Other ID:

• 00281789

UI: 102178719

From Meeting Abstracts